Asset Details
Do you wish to reserve the book?
Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma, Including Those Who are Triple‐Class Exposed: A Retrospective Cohort Study in England Using National Cancer Registry Data
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma, Including Those Who are Triple‐Class Exposed: A Retrospective Cohort Study in England Using National Cancer Registry Data
Do you wish to request the book?
Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma, Including Those Who are Triple‐Class Exposed: A Retrospective Cohort Study in England Using National Cancer Registry Data
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma, Including Those Who are Triple‐Class Exposed: A Retrospective Cohort Study in England Using National Cancer Registry Data
2025
Overview
Introduction Multiple myeloma (MM) prognosis worsens once patients become triple‐class exposed (TCE) to at least one treatment in each class: immunomodulators, proteasome inhibitors, and anti‐CD38 monoclonal antibodies. Methods We conducted a retrospective study using the Cancer Analysis System database to assess characteristics, treatment patterns, and clinical outcomes for adults diagnosed with MM between 2014 and 2020. The main cohort included patients ≥18 years‐old diagnosed with incident MM (including TCE patients) who had at least one record of systemic anticancer therapy treatment within 30 days prior to, on, or any time after their diagnosis. Results The main cohort comprised 14,990 patients, predominantly white and male, with a median age at diagnosis of 71 years. Of these, 848 (5.6%) became TCE. In the main cohort (n = 14,990), 57.2% of patients received only one line of therapy, and >50% of all first‐line regimens included bortezomib. Median overall survival (OS) from diagnosis was 51.5 months. After becoming TCE (n = 848), median OS was 13.2 months and median time to next treatment or death was 5.7 months. Conclusions This study provides current evidence on real‐world OS and management for patients with MM in England, including those who become TCE.
Publisher
John Wiley and Sons Inc,Wiley
Subject
